Gaps in the Treatment of Psoriasis and PsA for Systemic Therapy
|
|
- Paulina Wheeler
- 6 years ago
- Views:
Transcription
1 Gaps in the Treatment of Psoriasis and PsA for Systemic Therapy Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology Icahn School of Medicine at Mount Sinai
2 Disclosure Mark Lebwohl is an employee of Mount Sinai which receives research funds from: Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen / Johnson & Johnson, Kadmon, Medimmune/Astra Zeneca, Novartis, Pfizer, Valeant and ViDac. Dr. Lebwohl is also a consultant for Allergan, Aqua Leo-pharma,and Promius.
3 Research gaps in psoriasis: opportunities for future studies Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. J Am Acad Dermatol. 2014;70:146-67
4 Psoriasis outcome measures: a report from the GRAPPA 2012 annual meeting Gottlieb AB, Armstrong AW. J Rheumatol. 2013;40:
5 Research Gaps Can we predict who ll develop PsA and can we prevent it? Can we predict who ll develop other comorbidities (cardiac, renal, etc) and can we prevent them? Can we predict who ll respond to which therapy?
6 Can we predict who ll develop PsA? (Can we treat to prevent joint disease?)
7 Patient perspectives in the management of psoriasis: Results from the populationbased Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, Paul CF, Puig L, Reich K, van de Kerkhof PC. J Am Acad Dermatol Feb 24. [Epub ahead of print]
8 139,948 households were screened and 3426 patients prevalence of psoriasis/psa ranged from 1.4% to 3.3% 79% had psoriasis alone and 21% had PsA 27% (psoriasis) and 53% (PsA ± psoriasis) of patients rated it as severe 45% had not seen a physician in a year;
9 Psoriasis and Psoriatic Arthritis: Timing of Onset 21% Arthritis 1st 7% concurrent 72% Psoriasis 1st Psoriasis 1st Arthritis 1st concurrent
10 Subclinical Joint Involvement in Patients With Psoriasis Joint structural damage can occur before the appearance of clinical symptoms of PsA In a study by Offidani and colleagues, which used MRI rather than conventional radiography to assess joint involvement, 68% of patients with psoriasis were found to have 1 or more arthritic signs Appeared before patients experienced clinically evident joint symptoms Joint damage was only detected by X-ray imaging in 32% of these patients Source: Offidani A, et al. Acta Derm Venereol (Stockh). 1998;78:
11 Sharp score or van der Heijde score measures joint damage on x-ray: narrowing and erosions Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. van der Heijde DM, et al Arthritis Rheum Jan;35(1):26-34.
12 Mean Change in mtss* From Baseline Etanercept for Psoriatic Arthritis: Radiographic Improvement ** Study Month Etanercept 25 mg biw (n=101) Placebo (n=104) OLE completers originally randomized to etanercept (n=71) OLE completers originally randomized to placebo (n=70) *X-rays of hands and wrists (includes DIP joints); **P =.0001 vs placebo (stratified rank test). Start of OLE. Source: Mease P, et al. Arth Rheum. 2004;50: Lebwohl M, et al. Presented at: 63rd Annual Meeting of AAD; February 18-22, 2005; New Orleans, La. (Abstract P2753).
13 Mean Change in mtss Adalimumab for Psoriatic Arthritis: Radiographic Results Mean Change in mtss Through Week Placebo Adalimumab Weeks N Baseline 24 Wk Mean Change 48 Wk Mean Change Placebo Adalimumab * 0.1 *P.001 vs placebo for ranked ANCOVA. Sources: Mease P, et al. Arth Rheum. 2005;52: Mease P, et al. Presented at: EULAR Annual Meeting; June 8-11, 2005; Vienna, Austria. * 48
14 Total vdh-s Score Total vdh-s Score Mean Change from Baseline at Week 24* p< *Median Change in both groups was Placebo (n=100) Infliximab 5 mg/kg (n=100) Van der Heijde D, et al. Ann Rheum Dis. 2005;64 (Supplement III):109.
15 Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longerterm outcomes including enthesitis and dactylitis with golimumab treatment in the Long term Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). Kavanaugh A, Mease P. J Rheumatol Suppl Jul;89:90-3.
16 Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D, Woltering F, Stach C, Hoepken B, Arledge T, van der Heijde D. Ann Rheum Dis. 2014;73:48-55.
17 % achieving response PALACE 1: Apremilast in PsA (Phase 3) Apremilast, oral phosphodiesterase 4 (PDE4) inhibitor RDBPC trial stratified for DMARD use, N=489, 1:1:1 randomization Major adverse events diarrhea and nausea, resolve over time Week 16 Week * Placebo Apremilast 20mg BID Apremilast 30mg BID *P<0.05; P< ACR20 ACR20 ACR50 ACR70 Kavanaugh A et al, ACR 2012, Washington, #L13
18 Mean Change from Baseline Change From Baseline in Modified Total vdhs Score Over Time (ITT) USTEKINUMAB PSUMMIT I and II 0.0 Week 0 Week 24 Week 52 Placebo (n=310) UST 45 mg (n=308) Placebo 45 mg at Wk 24 (n=269)* UST 90 mg (n=309) *Patients who did not receive UST are excluded
19 Mean change in vdh-mtss FUTURE 1: Radiographic progression in PsA patients stratified by MTX use Baseline to Week 24 (full analysis set) Pooled SKB doses PBO SECUKINUMAB * * Overall population MTX: Yes MTX: No *P<0.05 vs PBO Change in mtss >0.5 considered progression of radiographic disease Gottlieb AB, et al. EADV 2015, P0348 Sponsored by Novartis Pharma AG
20 Ixekizumab, an interleukin-17a specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Mease PJ, et al Ann Rheum Dis. 2017;76: IXEKIZUMAB
21 IXEKIZUMAB Ixekizumab, an interleukin-17a specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Mease PJ, et al; Ann Rheum Dis. 2017;76:79-87.
22 Patients (% ± SE) Patients (% ± SE) Brodalumab Phase 2 PsA study: Clinical response and improvement in psoriasis in subjects with PsA * * ACR20 response rate at Week 24 PBO (n=55) BRO 140 mg q2w (n=57) BRO 280 mg q2w (n=56) ACR20 * * Open label Week Number of subjects PBO mg mg Indicates time point at which all subjects began receiving BRO 280 mg q2w ACR50 BRODALUMAB * * Open label Week Number of subjects PBO mg mg Mease P, et al. AAD 2014, P7605
23 We don t have a serologic marker that predicts psoriatic arthritis or its severity
24 Research Gaps Can we predict who ll develop PsA and can we prevent it? Can we predict who ll develop other comorbidities (cardiac, renal, etc) and can we prevent them? Can we predict who ll respond to which therapy?
25 Risk of myocardial infarction in patients with psoriasis. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. JAMA 2006;296:
26 Does treatment of psoriasis reduce the risk of cardiovascular disease? Churton S, Brown L, Shin TM, Korman NJ. Drugs. 2014;74:169-82
27 Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to antitumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007;56(9):
28 Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Wu JJ, Poon KY, Channual JC, Shen AY Arch Dermatol. 2012;148:
29 Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. BMJ. 2013;347:f5961
30 Research Gaps Can we predict who ll develop PsA and can we prevent it? Can we predict who ll develop other comorbidities (cardiac, renal, etc) and can we prevent them? Can we predict who ll respond to which therapy?
31 Cost of Biologics: Year 1 Etanercept: ~$79,623 Adalimumab: ~ $69,670 Ustekinumab: ~$52, ,015 Infliximab: ~$22,995-80,482 ( kg q4-8w. at 5mg/kg) Secukinumab: ~$75,007 Ixekizumab:~$82,891 Brodalumab:~$31,395 Guselkumab: ~$71, /21/18
32 Patients (%) ERASURE study results: Secukinumab rapidly improved plaque Ps, and sustained high responses through 52 weeks ERASURE SEK 300 mg (n=245) SEK 150 mg (n=245) Placebo (n=247) b PASI 75 Response 87.8% SECUKINUMAB * * Weeks *p< vs placebo at Wk 12. Grey arrows indicate peak response a IGA score of 0 (clear) or 1 (almost clear) and an improvement of at least 2 points on the IGA scale compared with baseline; b One subject did not sign informed consent before starting study procedures and was excluded from analyses Elewski B, et al. EADV 2013: P1501. Sponsored by Novartis Pharma AG
33 Patients (%) ERASURE study results: Secukinumab rapidly improved plaque Ps, and sustained high responses through 52 weeks ERASURE SEK 300 mg (n=245) SEK 150 mg (n=245) Placebo (n=247) b PASI 90 Response PASI 100 Response * * * * Weeks Weeks *p< vs placebo at Wk 12 a IGA score of 0 (clear) or 1 (almost clear) and an improvement of at least 2 points on the IGA scale compared with baseline; b One subject did not sign informed consent before starting study procedures and was excluded from analyses Elewski B, et al. EADV 2013: P1501. Sponsored by Novartis Pharma AG
34 Percent of Responders BRODALUMAB PASI 75 Response Rate (NRI) by Week in the Induction Phase 100% 80 % 60 % 40 % 20 % 0% AMAGINE Visit Week 86.3% 77.0% 70.0% 66.6% 8.09% 12 Placeb o Ustekinumab 140 mg Q2W 210 mg Q2W Weight-Based Data on file, Amgen. 34
35 Percent of Responders BRODALUMAB PASI 90 Response Rate (NRI) by Week in the Induction Phase 80% 60 % 40 % AMAGINE % 58.7% 49.3% 47.0% 20 % 0% Visit Week % Placeb o Ustekinumab 140 mg Q2W 210 mg Q2W Weight-Based Data on file, Amgen. 35
36 Percent of Responders BRODALUMAB PASI 100 Response Rate (NRI) by Week in the Induction Phase 50% 40 % 30 % 20 % 10 % 0% AMAGINE Visit Week 44.4% 33.6% 25.7% 21.7% 0.65% 12 Placeb o Ustekinumab 140 mg Q2W 210 mg Q2W Weight-Based Data on file, Amgen. 36
37 IXEKIZUMAB
38 Sensitivity / Specificity IXEKIZUMAB PASI 50 at Wk 4 optimal for predicting PASI 75 at Wk 12 Predictability for PASI 75 at Wk 12 at different percentages of PASI improvement at Wk 4 (combined groups) Sensitivity Specificity Optimal threshold* PASI improvement at Week 4 *Optimal threshold at PASI48; PASI 50 selected for practicality Good overall sensitivity (83%), specificity (87%), positive predictive value (90%), and negative predictive value (77%) Combining results for 75 and 150 mg groups showed similar results PASI 50 responders at Wk 4 were called early responders Zhu B, et al. EADV 2012: P952
39 % Patients Early responders had significantly higher improvement in PASI 75 and 100 than non-responders *** *** *** * *p<0.05; **p<0.01; ***p<0.001 vs non-responder group ** *** Weeks PASI 75 Weeks PASI 10S0 IXEKIZUMAB Zhu B, et al. EADV 2012: P952
40 Week 16 Partial Responders (50 PASI < 75) and Nonresponders (25 PASI < 50) That Achieved PASI 50, 75, or 90 at Week 28 UST Combined* 50 PASI < 75 at Week PASI < 50 at Week 16 Patients at Week 16, n Achieve PASI 50 at Week 28 98% 71% Achieve PASI 75 at Week 28 52% 13% Achieve PASI 90 at Week 28 13% 2% USTEKINUMAB *Combined data for PHOENIX 1 and 2 patients 100kg receiving 45 mg UST and >100kg receiving 90 mg UST. Sobell J, et al. Poster Presentation at FCD 2010.
41 Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. Weinberg JM. Cutis. 2003;72:396-8.
42 Successful treatment of hand and foot psoriasis with infliximab. Di Lernia V, Guareschi E. Dermatol Online J ;16:8. Severe psoriasis pustulosa palmaris et plantaris (Barber-Königsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept). Kasche A, et al J Eur Acad Dermatol Venereol.2007;21:255-7.
43 Safety and efficacy of Adalimumab in the treatment of moderate to severe palmo-plantar psoriasis: an open label study. Clin Ter. 2012;163(2):e61-6. Richetta AG, et al 4/11 clear 5/11 50% improvement
44 Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis of PP pustulosis; results from a randomized controlled trial. Bissonnette R et al. JEADV 2013 DOI: /jdv UST 45mg doesn t work
45 Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-tosevere palmoplantar psoriasis. J Dermatolog Treat May 8. [Epub ahead of print] Au SC, Goldminz AM, Kim N, Dumont N, Michelon M, Volf E, Hession M, Lizzul PF, Andrews ID, Kerensky T, Wang A, Yaniv S, Gottlieb AB. 7/20 clear (90 mg:6/9; 45mg:1/11) 12/20 >2point PGA approval
46 An investigator-initiated, open-label study evaluating the efficacy and safety of UST in patients with moderate-tosevere palmar/plantar psoriasis 24 subjects with palmar/plantar psoriasis with PGA 3 treated with FDA-approved dose of UST using weight-based dosing Report of 20/24 subjects, 11 in 45-mg dose, 9 in 90-mg dose. Mean weight of subjects not reported Shimrat Y, et al. AAD 2012: P4733; Study sponsored by Centocor
47 Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. Bissonnette R, et al. J Am Acad Dermatol Mar 24. pii: S (16) doi: /j.jaad [Epub ahead of print]
48 Patients Achieving PPPGA 0 or 1 (%) PPPGA 0 or 1 Achievement at Week 16 in Patients With Baseline PPPGA * PSOR ESTEEM 1 Placebo Apremilast 30 mg BID 65.4 n/m = 2/10 6/ 8/26 22/57 5/16 17/2 9 6 ESTEEM 2 *P<0.05 vs. placebo. Includes patients with Palmoplantar Psoriasis Physician Global Assessment (PPPGA) 3, indicating moderate or severe palmoplantar psoriasis, at baseline; all data are last observation carried forward. n/m=number of patients with response/number of patients with sufficient data for evaluation. *
49 % Patients Achieving Change from Baseline in ESIF Score of >4.98 Clinical and patient-reported improvements of hand and/or foot psoriasis with ADA 40 mg qow: Subanalysis of REACH Subanalysis of REACH study looking at elements of erythema, scaling, induration and fissuring (ESIF) score along with DLQI Patients achieving a change from baseline in ESIF score of >4.98 Week 16 Week 28 PBO ADA Non-responder imputation. ESIF: Erythema, scaling, induration, fissuring. Menter A, et al. AAD 2012: P5061; Study sponsored by Abbott Laboratories
50 Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, Hugot S, Milutinovic M. J Am Acad Dermatol Oct (epub ahead of print)
51 Journal of the American Academy of Dermatology DOI: ( /j.jaad )
52 Journal of the American Academy of Dermatology DOI: ( /j.jaad )
53 More than Half of All Subjects on Secukinumab 300 mg Achieved Clear/Almost Clear Palms and Soles at 1.5 Years ppiga 0/1 Response Out to 1.5 Years 57.2% pppasi Change Out to 1.5 Years 39.4%** 35.3%*** 52.4%*** 34.9% 23.1%* 1.5% 54.6%*** 69.5% Palmoplantar disease improved by approximately 70% at 1.5 years in subjects receiving secukinumab 300 mg
54 Patients (%) UNCOVER-3: Ixekizumab in patients with palmoplantar involvement: pppasi 75 response rates Placebo/IXE q4w (n=20) IXE q4w/ixe q4w (n=32) ETN/IXE q4w (n=25) IXE q2w/ixe q4w (n=38) Placebo washout Induction dosing period * * 78.1* 68.4* 44.0 Open label, long term extension period (IXE q4w) Weeks These patients have plaque psoriasis of the hands and feet, this does not address efficacy in pustular disease nor patients with predominantly palmoplantar disease Menter A, et. al. EADV 2016, FC03.08; Sponsored by Eli Lilly and Company
Psoriasis Patients with: Integrating New Psoriasis Therapies Into Your Practice
Integrating New Psoriasis Therapies Into Your Practice Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology The Mount Sinai School of Medicine Psoriasis Patients with: Psoriatic
More informationBiologics and Psoriasis: The Beat Goes On
Biologics and Psoriasis: The Beat Goes On Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is
More informationWhat s New in the Treatment of Psoriasis
What s New in the Treatment of Psoriasis Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Mark Lebwohl is an
More informationBiologics in Psoriasis. Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre
Biologics in Psoriasis Peter CM van de Kerkhof Department of Dermatology Radboud University Nijmegen Medical Centre Disclosures Consultancy services for Celgene, Centocor, Almirall, Amgen, Pfizer, Philips,
More informationBreakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING
More informationBiologics in Psoriasis: 2018 and Beyond. Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research
Biologics in Psoriasis: 218 and Beyond Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Biologics in Psoriasis FDA approved TNF inhibitors Etanercept Adalimumab
More informationResearch Developments in Psoriasis Treatment A CME Activity
Overview Research Developments in Psoriasis Treatment A CME Activity Mark Lebwohl, MD, Waldman Chair of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, provides his perspectives
More informationThe Cosentyx clinical trial programme 1-11
The Cosentyx clinical trial programme 1-11 There are eight pivotal trials (four in psoriasis, two in psoriatic arthritis, two in ankylosing spondylitis) There are two head-to-head trials in psoriasis showing
More information(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationIncorporating Biologics Into Your Practice
Incorporating Biologics Into Your Practice Jeffrey M. Sobell MD Tufts University School of Medicine SkinCare Physicians Ora Clinical Research Disclosure Of Relationships With Industry Amgen AbbVie Celgene
More informationAbstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationPsoriasis Pearls. Mark Lebwohl, MD
Psoriasis Pearls Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Psoriasis Pearls Pearl #1 Patients who can
More informationEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
More informationWhat s New in Medical Dermatologic Therapy
What s New in Medical Dermatologic Therapy Mark Lebwohl, MD Waldman Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationP4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling
P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling Mark Lebwohl, 1 Andrew Blauvelt, 2 Matthias Augustin, 3 Yang Zhao, 4 Isabelle Gilloteau,
More informationEvaluating Psoriasis: Patient Reported Outcomes and Impact of Disease
Evaluating Psoriasis: Patient Reported Outcomes and Impact of Disease Bruce E. Strober, MD, PhD Professor and Chair Department of Dermatology University of Connecticut Farmington, Connecticut DISCLOSURE
More informationThe role of current biologic therapies in psoriasis
: An Update on and IL-17 Inhibitors Joanna Dong, BA; Gary Goldenberg, MD PRACTICE POINTS The newest biologics for treatment of moderate to severe plaque psoriasis are and IL-17 inhibitors with unprecedented
More informationPsoriatic Arthritis: New and Emergent Therapies
Psoriatic Arthritis: New and Emergent Therapies Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS
More informationIxekizumab. Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A. Απρίλιοσ 2018 ΕΠΕΜΥ Πόρτο Χέλι
Ixekizumab Η νέα θεραπευτική προςέγγιςη ςτη ΨΑ μέςω τησ αναςτολήσ τησ IL-17A Απρίλιοσ 218 ΕΠΕΜΥ Πόρτο Χέλι ΣΑΜΑΣΗ-ΝΙΚΟ ΛΙΟΗ Καθηγ. Ρευματολογίας Ιατρική χολή Παν. Πατρών Ixekizumab Στοιχεία για το mab
More informationDisclosures. Activity Information. Updates in Psoriasis Therapy. Ustekinumab Guselkumab Tildrakizumab. Secukinumab Ixekizumab Brodalumab
Disclosures Faculty: Teri Greiling, MD, PhD, has disclosed the following conflicts of interest: research funding: Eli Lilly. Updates in Psoriasis Therapy 12 October 2018 St. Charles Medical Center Teri
More informationJEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationRheumatology journal club October 20, 2017 Presented by: Matthew Stoll MD,PhD,PSCS
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis (Mease et al., 2017) Rheumatology journal club October 20,
More informationPsoriasis. Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid
Psoriasis Dr. Pablo de la Cueva Hospital Universitario Infanta Leonor Madrid PSORIASIS Psoriasis News. Topical treatment Calcipotriene/Betamethasone Dipropionate (Cal/BD) foam: In the real-world, Cal/BD
More informationPublic observer slides
Public observer slides Lead team presentation Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2104-4 Program Prior Authorization/Medical Necessity Medication Taltz (ixekizumab) P&T Approval Date 8/2016, 5/2017, 2/2018 Effective
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Apremilast Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 4 References... 4 Effective Date... 1/1/2018 Next
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationThe New and Emerging Agents: Dermatology
Psoriasis Treatment 2013: What is New and on the Horizon? Neil J Korman, MD, PhD Professor of Dermatology University Hospitals Case Medical Center Clinical Director Murdough Family Center for Psoriasis
More informationWhat's Now, What's Next: Individualizing the Treatment of Patients With Moderate to Severe Psoriasis for the Dermatologist Presentation 1
The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants from Celgene
More informationMedication Prior Authorization Form
Policy Number: 1055 Policy History Approve Date: 06/01/2018 Effective Date: 06/01/2018 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for certain service(s)
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationSource: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California
Source: American Academy of Dermatology Annual Meeting held February 16 20, 2018, in San Diego, California OVERVIEW Steven R. Feldman, MD, PhD, and Alan Menter, MD, as well as principal investigators,
More informationPsoriasis: Therapeutic goals
Psoriasis: Therapeutic goals I want to die 50 45 impetiginization infliximab 600 40 35 30 400 25 20 15 200 10 5 0 22-ene 21-feb 23-mar 22-abr 22- may Efalizumab 6 doses: flare + REBOUND CSA 3 21-jun 21-jul
More informationIL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future
IL-23 Inhibition in Psoriasis: Changing the Present, Shaping the Future This symposium took place on 13 th September 2018, as part of the 27 th European Academy of Dermatology and Venereology (EADV) Congress
More informationSTELARA (USTEKINUMAB)
Oxford STELARA (USTEKINUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 218.13 T2 Effective Date: February 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationchemotherapeutic agents in
Use of biologics and chemotherapeutic agents in cutaneous emergencies: Focus on lifethreatening forms of psoriasis Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan
More informationPGA x BSA as a PASI Surrogate
PGA x BSA as a PASI Surrogate Alice Bendix Gottlieb MD, PhD Professor of Dermatology New York Medical College Metropolitan Hospital New York, NY, USA DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY
More informationADDITIONAL RESOURCES
ADDITIONAL RESOURCES CURRENT MODEL OF PSORIASIS IMMUNOPATHOGENESIS IL-17 A/FIL-22 GM-CSF Stressed keratinocytes TNF-α Myeloid dendritic cell Keratinocytes Activation IL-23 IL-12 T cells IL-1 BIL-6 TNF-α
More informationThe Natural History of Psoriasis and Treatment Goals
The Natural History of Psoriasis and Treatment Goals Psoriasis Epidemiology Prevalence Affects 2 3% of adult population (>7 million in US) Caucasians: 25% 2.5% African Americans: 1.3% (more likely to have
More informationPsoriasis: Which Drug for Which Patient? Mark Lebwohl, MD
Psoriasis: Which Drug for Which Patient? Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai DRUG PsA
More informationTargeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value
Targeted Immunomodulators for the Treatment of Moderate-to- Severe Plaque Psoriasis: Effectiveness and Value Condition Update Final Background and Scope January 9, 2018 Background Psoriasis is a common
More information5/4/2018. Disclosures. PsA: A heterogeneous disease. Objectives. PsA: A heterogeneous disease Fatigue
5//18 Disclosures Management of Psoriatic Arthritis Alexis Ogdie, MD MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Psoriatic Arthritis Clinic Division of Rheumatology Center for
More informationMark G. Lebwohl 1 Arthur Kavanaugh
Am J Clin Dermatol (2016) 17:87 97 DOI 10.1007/s40257-015-0169-x ORIGINAL RESEARCH ARTICLE US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the
More information1 Introduction. Kim A. Papp 1 April W. Armstrong. Wendell Valdecantos 4
Am J Clin Dermatol (216) 17:79 86 DOI 1.17/s4257-15-161-5 ORIGINAL RESEARCH ARTICLE Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis
More informationJashin J Wu, 1 Alexander Egeberg, 2 James A Solomon, 3,4,5 Olawale Osuntokun, 6 Orin Goldblum, 6 Susan R Moriarty, 6 Fangyi Zhao, 6 Neil Korman 7
4662 Ixekizumab Treatment Shows a Neutral Impact on the Glucose and Lipid Profile of Patients with Moderate-to-Severe Psoriasis: Results from UNCOVER-1, -2, and -3 Jashin J Wu, 1 Alexander Egeberg, 2 James
More informationSTELARA (USTEKINUMAB)
STELARA (USTEKINUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0045J Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationDo Psoriasis Therapies Increase the Risk of Skin Cancer? Mark Lebwohl, MD
Do Psoriasis Therapies Increase the Risk of Skin Cancer? Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Department of Dermatology The Mount Sinai School of Medicine Disclosure Mark Lebwohl
More informationUse of medical record databases to study psoriasis
Use of medical record databases to study psoriasis Joel M. Gelfand, MD, MSCE Professor of Dermatology and Epidemiology Vice Chair for Clinical Research Medical Director, Clinical Studies Unit Director,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationBody Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab
Am J Clin Dermatol (16) 17:691 699 DOI 1.7/s257-16-229-x ORIGINAL RESEARCH ARTICLE Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab April
More informationSTELARA (USTEKINUMAB)
STELARA (USTEKINUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 218.15 T2 Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE... 1
More informationEvaluating Biologic Therapies for Psoriasis Strategies to Reduce Cost and Improve Patient Access and Outcomes
Evaluating Biologic Therapies for Psoriasis Strategies to Reduce Cost and Improve Patient Access and Outcomes Faculty William J. Cardarelli, PharmD Director of Pharmacy Revenue and Supply Atrius Health
More informationNational Doral, Miami, Florida 7:20 AM 8:20 AM, Ballroom B. Supported by an educational grant from Novartis Pharmaceuticals Corporation.
National Doral, Miami, Florida 7:20 AM 8:20 AM, Ballroom B Supported by an educational grant from Novartis Pharmaceuticals Corporation. Allan Gibofsky, MD, JD, MACR, FACP, FCLM Weill Medical College of
More informationFormulary Decisions and the Evolution of Psoriasis Treatment
perspectives Formulary Decisions and the Evolution of Psoriasis Treatment William Malatestinic, PharmD, MBA; 1 David Amato, MD; 1 Steven R. Feldman, MD, PhD 2 affiliations: 1 Eli Lilly and Company, Indianapolis,
More informationWhen researchers discovered in 1979 that the immunosuppressant
The Evolving Landscape of Psoriasis Treatment April W. Armstrong, MD, MPH,* Kenneth B. Gordon, MD, M. Alan Menter, MD, and Jashin J. Wu, MD Abstract The process of discovering new drugs for plaque psoriasis
More informationOverview of the Last Decade Inflammatory Skin Diseases. Mark Lebwohl, MD
Overview of the Last Decade Inflammatory Skin Diseases Mark Lebwohl, MD ProfessorAnd Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationPharmacy Accreditation
EASING THE PATIENT BURDEN OF PSORIASIS AND PSORIATIC ARTHRITIS: THE ROLE OF THE SPECIALTY PHARMACIST Claire Lee, PharmD, CSP, CPHQ Clinical Quality Improvement Supervisor Diplomat Flint, Michigan Pharmacy
More informationThe Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review
Dermatol Ther (Heidelb) (2017) 7:425 446 DOI 10.1007/s13555-017-0207-0 REVIEW The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review
More informationApproximately 3% of the US adult population,
Disease Burden and Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Results From National Psoriasis Foundation Panel Surveys Emily Edson-Heredia, MPH; Baojin Zhu, PhD;
More informationPrimary Results Citation 2
Table S1. Adalimumab clinical trials 1 ClinicalTrials.gov Rheumatoid Arthritis 3 NCT00195663 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study. A multicenter, randomized, double-blind clinical
More informationEfficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Drugs R D (2017) 17:29 51 DOI 10.1007/s40268-016-0152-x REVIEW ARTICLE Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical
More informationJEADV SHORT REPORT. Abstract
DOI: 10.1111/jdv.15258 JEADV SHORT REPORT Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled
More informationSelective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
BioDrugs (2015) 29:327 339 DOI 10.1007/s40259-015-0144-3 REVIEW ARTICLE Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast Melinda Gooderham 1,3 Kim Papp 2,3 Published online: 19
More informationClinical Policy: Brodalumab (Siliq) Reference Number: CP.PHAR.375 Effective Date: Last Review Date: 05.18
Clinical Policy: (Siliq) Reference Number: CP.PHAR.375 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationDaily Oxymetazoline Cream Demonstrates High and Sustained Efficacy in Patients With Persistent Erythema of Rosacea Through 52 Weeks of Treatment
Accepted Manuscript Daily Oxymetazoline Cream Demonstrates High and Sustained Efficacy in Patients With Persistent Erythema of Rosacea Through 52 Weeks of Treatment Michael H. Gold, MD, FAAD, Mark Lebwohl,
More informationFaculty David M. Pariser, MD Professor Eastern Virginia Medical School Norfolk, VA
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of May 2015. The content and views presented in this educational activity are those of the
More informationintolerance to tumour necrosis
To cite: Nash P, Behrens F, Orbai A-M, et al. Ixekizumab is efficacious when used alone or when added to conventional synthetic diseasemodifying antirheumatic drugs (cdmards) in patients with active psoriatic
More informationPsoriasis and Psoriatic Arthritis Treatment
n REPORT n Psoriasis and Psoriatic Arthritis Treatment Alan Menter, MD Overarching Principles of Psoriasis and Psoriatic Arthritis Treatment Several best practices have emerged to guide the management
More informationClinical Policy: Ixekizumab (Taltz) Reference Number: ERX.SPA.122 Effective Date:
Clinical Policy: (Taltz) Reference Number: ERX.SPA.122 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMichael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research
Michael P. Heffernan, M.D San Luis Dermatology & Laser Clinic Director, US Probity Medical Research mpheffernanmd@gmail.com DISCLOSURES Consultant, Speaker, Investigator: Abbvie, Amgen, Brickell Biotech,
More informationProper treatment of psoriatic arthritis (PsA) requires. Update on Treatment of Psoriatic Arthritis. Philip Mease, M.D.
167 Update on Treatment of Psoriatic Arthritis Philip Mease, M.D. Abstract Some of this past year s key papers or abstracts on psoriatic arthritis (PsA) assessment and treatment are reviewed in this paper.
More informationTreatment of psoria.c arthri.s: Guidelines and beyond. Pascal RICHETTE Hôpital Lariboisière, Paris
Treatment of psoria.c arthri.s: Guidelines and beyond Pascal RICHETTE Hôpital Lariboisière, Paris The pa.ent: a 37 year- old man, with a history of psoriasis for 10 years Past history: - Dyslipidemia Current
More informationEmerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis These posters were presented at the 5 th World Psoriasis & Psoriatic Arthritis Conference 2018, held from 27 th 30 th June in Stockholm,
More informationBiologic Therapy in Psoriasis: Navigating the Options
CLINICAL REVIEW Biologic Therapy in Psoriasis: Navigating the Options Cather McKay, MD; Katherine E. Kondratuk, BS; John P. Miller, BS; Brittany Stumpf, MD; Erin Boh, MD, PhD PRACTICE POINTS Psoriasis
More informationCost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis
1108 Cost per Responder of Apremilast Versus Etanercept, Adalimumab, and Ustekinumab in Patients With Moderate to Severe Psoriasis Steven R. Feldman, MD, PhD 1 ; Tom Tencer, PhD 2 ; Zoe Clancy, PharmD,
More informationNEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes
Annual European Congress of Rheumatology (EULAR) 2017 Madrid, Spain, 14-17 June 2017 NEW EFFECTIVE TREATMENTS FOR PSORIATIC ARTHRITIS PATIENTS Promising data to support two new drug classes Madrid, Spain,
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More information3 rd Appraisal Committee meeting, 28 February 2017 Committee D
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying antirheumatic drugs Multiple Technology Appraisal 3 rd Appraisal Committee
More informationEffect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial
1152 Effect of Apremilast on Patient-Reported Outcomes in Patients With Moderate to Severe Plaque Psoriasis in the ESTEEM 1 Trial April W. Armstrong, MD, MPH 1 ; Christopher E.M. Griffiths, MD 2 ; Tom
More informationBJD British Journal of Dermatology. Summary. What s already known about this topic? What does this study add? CLINICAL TRIAL
CLINICAL TRIAL BJD British Journal of Dermatology Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab R.B. Warren,
More informationJ. Gelfand 1, A. Joshi 2, D. Shin 1, A. Dey 2, D. Torigian 1, D. Rader 1, M. Playford 2, M. Ahlman 2, A. Alavi 1, N. Mehta 2.
A Trial to Determine the Effect of Psoriasis Treatment (Adalimumab, Phototherapy, and placebo) on Cardiometabolic Disease: The Vascular Inflammation in Psoriasis (VIP) Trial Abstract 393 J. Gelfand 1,
More informationapremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.
apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd. 08 May 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationPsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.
RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright
More informationRESEARCH. What is already known about this subject. What this study adds
RESEARCH Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database Steven R. Feldman, MD,
More informationREVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS
REVEALING A CLEAR PATH TOWARDS A NEW ERA IN THE MANAGEMENT OF PSORIASIS Summary of Presentations from the Novartis-Supported Satellite Symposium, held at the 23 rd EADV Congress, Amsterdam, the Netherlands,
More informationSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant Thaçi, MD, a Andrew Blauvelt, MD, MBA, b Kristian
More informationBackground AN UPDATED LOOK AT TREATMENTS FOR PLAQUE PSORIASIS JULY 2018 PLAQUE PSORIASIS TARGETED IMMUNOMODULATORS AS A TREATMENT OPTION
JULY 2018 Background PLAQUE PSORIASIS Plaque psoriasis is a common disease affecting 3% of the US population that causes itchy, red, scaly, raised lesions on the skin, most commonly on the elbows, knees,
More informationIxekizumab improves patient-reported outcomes up to 52 weeks in bdmard-naïve patients with active psoriatic arthritis (SPIRIT-P1)
RHEUMATOLOGY Original article Rheumatology 2018;57:1777 1788 doi:10.1093/rheumatology/key161 Advance Access publication 25 June 2018 Ixekizumab improves patient-reported outcomes up to 52 weeks in bdmard-naïve
More informationApremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis
For Personal Use Only. Not For Distribution. Am J Clin Dermatol DOI 10.1007/s40257-017-0302-0 REVIEW ARTICLE Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis Tiago Torres 1,2 Luis
More informationEULAR UCB, Inc. All rights reserved. For unsolicited request only.
1 EULAR 213 2 CZP in AxSpA Effects of certolizumab pegol (CZP) on the signs and symptoms of AxSpA at week 24 (RAPID-AxSpA) 3 RAPID-AxSpA: Ongoing 24-week trial in adult patients with active AxSpA according
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationAnti-TNF biologic agents Dr Lluís Puig
Department of Dermatology Hospital de la Santa Creu i Sant Pau IPC NOVARTIS PSORIASIS PRECEPTORSHIP Anti-TNF biologic agents Dr Lluís Puig Barcelona, July 9th-10th, 2013 Anti-TNF therapy in the pathophysiology
More informationEfficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
Rheumatol Ther (2018) 5:567 582 https://doi.org/10.1007/s40744-018-0131-5 ORIGINAL RESEARCH Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies Peter
More informationUSTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE
Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA 36187 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of psoriatic arthritis (PsA)
More information